Advance and New Insights in Bladder Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 October 2022) | Viewed by 18480
Special Issue Editor
Interests: immunotherapy; urothelial cancer; surgery; marker; nodes; cystectomy; robotics; recurrence; progression; chemotherapy; minimally invasive techniques; active surveillance; ERAS
Special Issue Information
Dear Colleagues,
The potential readership of this special issue will expand their knowledge on the pathology and the molecular landscape in BCa and its treatment consequences, including variant (aberrant) pathologies, the molecular classification of BCa and the genomic approach in BCa. They will also be updated on diagnostics and staging of BCa, and learn about NMIBC, specifically endoscopic diagnosis and therapy, treatment optimisation and the role of local and new systemic approaches and their optimal timing. When it comes to MIBC, participants will learn specifically about surgery (both the role of TURB and Open vs. Robotics), about systemic therapy (neoadjuvant and adjuvant systemic chemotherapy and immunotherapy), and the bladder-sparing approach. Finally, participants will have been instructed on systemic therapy in metastatic bladder and urothelial cancer and have developed an understanding on BCa recurrence and follow-up.
Prof. Dr. Morgan Rouprêt
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- marker
- urinary
- urothelial
- carcinoma
- laparoscopic
- chemotherapy
- immunotherapy
- nodes
- surgery
- robotics
- prognosis
- recurrence
- progression
- ERAS
- follow-up
- cystoscopy
- imaging